| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/25/2007 | US20070021334 Class III slrp agonists for the reduction of blood vessel formation |
| 01/25/2007 | US20070021333 Pharmaceutical compositions based on anticholinergics and soluble tnf receptor fusion proteins |
| 01/25/2007 | US20070021332 Helminth-derived antigens having capacity of providing protection against parasites |
| 01/25/2007 | US20070021331 Methods of using macrocyclic modulators of the ghrelin receptor |
| 01/25/2007 | US20070021330 cyclic peptides used as enzyme inhibitors, optionally mixed with carriers or excipients, and viricides selected from interferons, ribavirin and amantadine, for treatment of viral diseases |
| 01/25/2007 | US20070021329 Treatment of hypersensitivity conditions |
| 01/25/2007 | US20070021328 Chloro-biphenyl-rearranged norvacomycin with improved antibacterial activity and less potential for developing resistance |
| 01/25/2007 | US20070021327 Methods and compositions for treatment of tumors using nucleic acid ligands to platelet-derived growth factor |
| 01/25/2007 | US20070021326 Composition and its Therapeutic Use |
| 01/25/2007 | US20070021325 Drug formulation containing a solubilizer for enhancing solubility, absorption, and permeability |
| 01/25/2007 | US20070021324 Process for preparation of mixtures of polypeptides using purified hydrobromic acid |
| 01/25/2007 | US20070021323 Use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer |
| 01/25/2007 | US20070021322 Chemical compositions may be selectively or preferentially excited by the application of scores comprising a series of energy inputs to change at least a subset of the group of proximate atoms from a first geometric configuration to a second geometric configuration different from the first |
| 01/25/2007 | US20070021321 determining whether catechin or an antibody has the same pharmacological effect as that of epigallocatechin gallate, on inhibiting cell proliferation, angiogenesis or cancer cell metastasis, as a neuroprotectant, a viricide, an antiallergen and as a antiarteriosclerotic agent |
| 01/25/2007 | US20070020734 Interferon-alpha polypeptides and conjugates |
| 01/25/2007 | US20070020730 Method for overexpression of zwitterionic polysaccharides |
| 01/25/2007 | US20070020729 Novel collectin |
| 01/25/2007 | US20070020728 Muteins of apolipoprotein D |
| 01/25/2007 | US20070020723 Ceramide kinase-like proteins |
| 01/25/2007 | US20070020703 Use of compositions comprising a soluble form of hla-g in the treatment of blood diseases |
| 01/25/2007 | US20070020694 Linking oligopeptide to a stabilizing group, linking the oligopeptide to a therapeutic agent, testing if the conjugate is cleavable by Thimet oligopeptidase |
| 01/25/2007 | US20070020684 Structure of a glucocorticoid receptor ligand binding domain comprising an expanded binding pocket and methods employing same |
| 01/25/2007 | US20070020679 Modulation of HIF1alpha and HIF2alpha expression |
| 01/25/2007 | US20070020674 Novel gene defective in APECED and its use |
| 01/25/2007 | US20070020673 Model of autoimmune disease and methods for identifying agents against autoimmune disease |
| 01/25/2007 | US20070020643 High affinity for streptavidin/avidin; biotinyl moiety linked to a photoreactive group covalently bound to substrate (proteins, peptides, amino acids, and nucleic acids); Exposure of the conjugate to radiation releases the target in a functional form and completely unaltered |
| 01/25/2007 | US20070020632 Method for selective inhibition of human n-myc gene in n-myc expressing tumors through antisense and antigen peptido-nucleic acids (pna) |
| 01/25/2007 | US20070020614 Development of novel anti-microbial agents based on bacteriophage genomics |
| 01/25/2007 | US20070020344 inhibition and/or prevention of on-growth of biological organisms on objects or living beings, includes at least one cyclotide, and a suitable carrier medium |
| 01/25/2007 | US20070020343 Nutrient supplements and methods for treating autism and for preventing the onset of autism |
| 01/25/2007 | US20070020336 Cyclodextrin nanotechnology for ophthalmic drug delivery |
| 01/25/2007 | US20070020295 Controlled release neurotoxin system and method |
| 01/25/2007 | US20070020294 Use of botulinum toxin for treatment of articular pathologies |
| 01/25/2007 | US20070020289 Preparations and processes for stabilizing biological materials by means of drying processes without freezing |
| 01/25/2007 | US20070020287 Virulence genes of M.marinum and M. tuberculosis |
| 01/25/2007 | US20070020285 prophylactic and therapeutic vaccination directed against the hepatitis C virus |
| 01/25/2007 | US20070020284 decreased protein degradation, increased stability and circulation time; for excess weight, diabetes, high blood lipid level, arteriosclerosis, arterial plaque, the reduction or prevention of gall stones formation, insufficient lean tissue mass, insufficient sensitivity to insulin, and stroke |
| 01/25/2007 | US20070020280 Compositions and methods for inhibition of HIV-1 infection |
| 01/25/2007 | US20070020277 Human Oncogene Induced Secreted Protein I |
| 01/25/2007 | US20070020275 Nucleic acid sequences of hyperplasia and tumours of the thyroid |
| 01/25/2007 | US20070020270 Human serpin polypeptides |
| 01/25/2007 | US20070020269 Phosphokinase and the usage thereof |
| 01/25/2007 | US20070020268 Treatment of inflammatory bowel disease with ifn-gamma inhibitors |
| 01/25/2007 | US20070020265 administering non-blocking anti-CD20 antibody and carrier; fusion proteins; rheumatoid arthritis |
| 01/25/2007 | US20070020263 Medicine containing genetically modified antibody against chemokine receptor ccr4 |
| 01/25/2007 | US20070020262 Uses of mammalian cytokine: related reagents |
| 01/25/2007 | US20070020260 Glycoprotein compositions |
| 01/25/2007 | US20070020258 Immunoglobulin variants |
| 01/25/2007 | US20070020257 Which induce an antibody specific to cell surface protein antigen from Streptococcus; use in vaccine production and preventing dental caries |
| 01/25/2007 | US20070020254 Methods and compositions for treatment of inflammatory disease |
| 01/25/2007 | US20070020253 Spleen tyrosine kinase catalytic domain:crystal structure and binding pockets thereof |
| 01/25/2007 | US20070020252 Modified protease inhibitors |
| 01/25/2007 | US20070020251 Administering to the cell all or part of a peptide isolated from the submaxiliary saliva glands of shrews of the species Blarina as a paralytic agent for inhibiting calcium uptake by a cancer cell |
| 01/25/2007 | US20070020249 Compositions for prevention and treatement of symptoms of gastrointestinal distress |
| 01/25/2007 | US20070020244 Fiber constructs and process of fiber fabrication |
| 01/25/2007 | US20070020235 Interferon-alpha polypeptides and conjugates |
| 01/25/2007 | US20070020234 Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor |
| 01/25/2007 | US20070020233 Administering monoclonal or polyclonal antibody to treat multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease |
| 01/25/2007 | US20070020232 Compositions and methods for cancer immunotherapy |
| 01/25/2007 | US20070020231 Remedy for kidney diseases |
| 01/25/2007 | US20070020230 Use of chemokines, and pharmaceutical preparations containing the same |
| 01/25/2007 | US20070020227 Use of truncated cysteine IL28 and IL29 mutants to treat cancers and autoimmune disorders |
| 01/25/2007 | US20070020225 Human placental collagen compositions, processes for their preparation, methods of their use and kits comprising the compositions |
| 01/25/2007 | US20070020224 Protein-proteophore complexes |
| 01/25/2007 | US20070020220 A dipeptide with a C terminal threonine formulated for oral or topical administration or injection; cosmetics for hair, skin, and nails; improved aging resistance |
| 01/25/2007 | US20070020219 Method for promoting hair growth |
| 01/25/2007 | US20070020199 Dispersible macromolecule compositions and methods for their preparation and use |
| 01/25/2007 | US20070020196 Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension |
| 01/25/2007 | US20070020192 Delivery of therapeutics conjugated to neonatal Fc receptor (FcRn) binding partner to intestinal, mucosal epithelium and epithelium of the lung; elicit immune response; systemic delivery of an interferon across an epithelial barrier |
| 01/25/2007 | US20070020191 Potentiation of glucose elimination |
| 01/25/2007 | US20070017513 Method and apparatus for dispensing inhalator medicament |
| 01/25/2007 | DE102005033630A1 Calcium-Peptid-Komponente Calcium peptide component |
| 01/25/2007 | DE10163333B4 Modifizierte Tridegine, ihre Herstellung deren Verwendung als Transglutaminase Inhibitoren und diese enthaltende Arzneimittel und Kombinationspräparate Modified Tridegine, their preparation and their use as medicaments containing transglutaminase inhibitors and compounds |
| 01/25/2007 | CA2790675A1 Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps |
| 01/25/2007 | CA2616156A1 Rh-epo nasal formulations with low sialic acid concentration for the treatment of diseases of the central nervous system |
| 01/25/2007 | CA2616125A1 Truncated oxidized thymosin .beta.4 and derivatives thereof |
| 01/25/2007 | CA2616122A1 Il28 and il29 truncated cysteine mutants and antiviral methods of using same |
| 01/25/2007 | CA2615990A1 Enhanced ocular neuroprotection/neurostimulation |
| 01/25/2007 | CA2615902A1 Delta 6 desaturase from thraustochytrid & its uses thereof |
| 01/25/2007 | CA2615887A1 Reduction in myocardial infarction size |
| 01/25/2007 | CA2615744A1 Plexin d1 as a target for tumor diagnosis and therapy |
| 01/25/2007 | CA2615562A1 Glycosylated il-7, preparation and uses |
| 01/25/2007 | CA2615491A1 Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps |
| 01/25/2007 | CA2615370A1 Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders |
| 01/25/2007 | CA2615006A1 Modulation of granulosa cell apoptosis |
| 01/25/2007 | CA2614959A1 Use of inhibitors of the ubiquitin proteasome pathway for increasing contractility of the heart |
| 01/25/2007 | CA2614811A1 Process for the manufacture of eptifibatide |
| 01/25/2007 | CA2614567A1 Heterodimeric four helix bundle cytokines |
| 01/25/2007 | CA2610237A1 Identification of a novel bitter taste receptor t2r76 that specifically responds to brucine and prop bitter ligands |
| 01/25/2007 | CA2578613A1 Binding domain fusion proteins |
| 01/24/2007 | EP1746162A2 Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| 01/24/2007 | EP1746161A1 Glycosylated IL-7, preparation and uses |
| 01/24/2007 | EP1746160A2 Hepatocyte growth factor receptor antagonists and uses thereof |
| 01/24/2007 | EP1746107A2 Antibody variants and fragments thereof |
| 01/24/2007 | EP1746106A2 Use of TACI as an anti-tumor agent |
| 01/24/2007 | EP1745801A1 Method of inhibiting telomerase activity and inhibitor |
| 01/24/2007 | EP1745799A2 Compositions and methods of treating tumors |
| 01/24/2007 | EP1745797A2 Vascularization inhibitors |
| 01/24/2007 | EP1745293A1 Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 9 (dpp9) |
| 01/24/2007 | EP1745142A2 Probiotic compounds from lactobacillus gg and uses therefor |